可溶性转化生长因子-β受体Ⅱ和 IFN-γ融合蛋白增强逆转肝纤维化的作用。

Enhanced effect of soluble transforming growth factor-beta receptor II and IFN-gamma fusion protein in reversing hepatic fibrosis.

机构信息

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Zhejiang University School of Medicine, China.

出版信息

Eur J Med Res. 2010 Apr 8;15(4):152-61. doi: 10.1186/2047-783x-15-4-152.

DOI:10.1186/2047-783x-15-4-152

PMID:20554496

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3474166/

Abstract

OBJECTIVE

To examine the in vivo anti-fibrotic effect of rat soluble transforming growth factor beta receptor II (RsTbetaRII) and IFN-gamma fusion protein (RsTbRII-IFN-gamma) in rat hepatic fibrosis model.

METHODS

Model rats were divided into five groups and treated i.m. for 8 weeks: 1) fibrotic model group (each rat, 100 microl of 0.9% NaCl day superset-1); 2) RsTbetaRII-IFN-gamma treatment group (each rat, 0.136 mg x day(-1); 3) IFN-gamma treatment group (each rat, 7.5 MU x day(-1); 4) RsTbetaRII treatment group (each rat, 0.048 mg x day(-1); and 5) mixture of IFN-gamma and RsTbetaRII treatment group (each rat, IFN-gamma 7.5 MU x day(-1)+ RsTbetaRII 0.048 mg x day(-1). After treatment, hepatic fibrogenesis was evaluated by histopathological analysis and measurement of collagen III, alpha-smooth muscle actin (alpha-SMA), TGF-beta1, TGF-betaRII and their mRNA.

RESULTS

Immunohistochemistry, Western blot and real-time RT-PCR showed that RsTbetaRII-IFN-gamma treatment significantly inhibited liver expression of collagen III, alpha-SMA, TGF-beta1 and TGF-betaRII at both protein and mRNA levels. Histopathological analysis also showed that the enhanced anti-fibrotic effects were achieved in model rats treated with RsTbetaRII-IFN-gamma.

CONCLUSION

Our results confirmed that RsTbetaRII-IFN-gamma has the enhanced effects in reversing hepatic fibrosis.

摘要

目的

研究大鼠可溶性转化生长因子β受体Ⅱ（RsTβRⅡ）与 IFN-γ融合蛋白（RsTbRⅡ-IFN-γ）在大鼠肝纤维化模型中的体内抗纤维化作用。

方法

模型大鼠随机分为 5 组，肌肉注射给药 8 周：1）纤维化模型组（每只大鼠，100 μl 0.9%NaCl 日剂量-1）；2）RsTbRⅡ-IFN-γ治疗组（每只大鼠，0.136mg·d-1）；3）IFN-γ治疗组（每只大鼠，7.5MU·d-1）；4）RsTβRⅡ治疗组（每只大鼠，0.048mg·d-1）；5）IFN-γ和 RsTβRⅡ混合治疗组（每只大鼠，IFN-γ7.5MU·d-1+RsTβRⅡ0.048mg·d-1）。治疗后，通过组织病理学分析和胶原 III、α-平滑肌肌动蛋白（α-SMA）、TGF-β1、TGF-βRⅡ及其 mRNA 的测量来评估肝纤维化。